RecruitingPseudomyxoma Peritonei
Pseudovax - A Cancer Vaccine for Patients With Pseudomyxoma Peritonei
Eligible age
18+ yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Participants will receive vaccination with Pseudovax/GM-CSF in combination with PD-1 inhibitor tislelizumab over a period of up to two years. The vaccine is expected to reactivate measurable immune response, and tislelizumab to restore anticancer immunity in patients with GNAS mutated pseudomyxoma peritonei.
Sponsor: Oslo University Hospital
You may qualify if…
- ✓ 1. The subject is ≥ 18 years of age on the day of signing the informed consent form, able to provide written informed consent and can understand and agree to comply with the requirements of the study and the schedule of assessments.
- ✓ 2. Confirmed diagnosis of recurrent or non-resectable PMP with no other available treatment options that are expected to be efficacious.
- ✓ 3. The subject's tumor must carry a mutation in the GNAS oncogene\*
- ✓ 4. Subjects must have peritoneal tumor distribution at screening that, in the opinion of the Investigator, is suitable for repeat biopsies: Up to 3 biopsies of target tissue are planned for subjects that complete the study.
- ✓ 5. Adequate organ, bone marrow, liver, and renal function at screening, including:
- ✓ 1. Absolute neutrophil count: ≥ 1,5 x109/L
- ✓ 2. Platelets: ≥ 100 x109/L
- ✓ 3. Hemoglobin: ≥ 9 x109/L
You may not qualify if…
- ✕ 1. Patient has Eastern Cooperative Oncology Group performance status 2 or worse.
- ✕ 2. Blood transfusion or growth factor support ≤ 14 days before sample collection at screening.
- ✕ 3. Active malignancy the past 3 years except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated curatively (e.g., resected basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast)
- ✕ 4. Enrollment in another interventional trial that, in the opinion of the Investigator, could influence the outcome of this study.
- ✕ 5. Subject has within the last 30 days received any other interventional therapy that, in the opinion of the Investigator, could influence the outcome of this study.
- ✕ 6. Pregnancy or lactating female.
- ✕ 7. Known active hepatitis B or C, or is known to be HIV-positive.
- ✕ 8. Any condition that required systemic treatment with either corticosteroids (\> 10 mg daily of prednisone or equivalent) or other immunosuppressive medication ≤ 14 days before the first dose of IMP.
Source: ClinicalTrials.gov · NCT07341360 · last updated 2026-01-14